Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, +10

The Lancet Rheumatology

Rheumatoid DisorderRheumatologyIntegrated Safety AnalysisMedicinePatient Safety +8

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

Masayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi, +9

RMD Open

Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma

X.R. Li, Feiyang Ji, Jun Ouyang, +3

European Journal of Surgical Oncology

Tumor BiologyHepatologyMedicinePathologyPoor Prognosis +5

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Julio Rosenstock, Stanley H. Hsia, Luis Nevárez Ruiz, +9

New England Journal of Medicine

Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study

Gee‐Chen Chang, Chien‐Hua Tseng, Kuo-Hsuan Hsu, +14

Lung Cancer

Non-small-cell Lung CancerMedicinePredictive FactorsPathologyBronchial Neoplasm +5

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Wen‐Shuo Wu, Yuh-Min Chen, Chun-Ming Tsai, +10

Experimental and Therapeutic Medicine

MedicineSimilar EfficacyBetter EfficacyPathologyTreatment Response +12

Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD)

Qiang Shi, Ko‐Jen Li, Tamás Treuer, +6

PLoS ONE

Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

Ying‐Chou Chen, Dae‐Hyun Yoo, Chang Keun Lee, +7

International Journal of Rheumatic Diseases

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer

Wen‐Shuo Wu, Yuh-Min Chen, Chun-Ming Tsai, +4

Journal of the Chinese Medical Association

<p>Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS)</p>

Chung‐Hwan Chen, Seung‐Jae Lim, Jong‐Keon Oh, +11

Clinical Interventions in Aging